Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not yet recruiting

Evaluation of V-Cu64 versus V-Ga68 PET-CT imaging in adults with diagnosed or suspected neuroendocrine tumors

Registered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study focuses on patients who have or are suspected of having neuroendocrine tumors. These are growths that arise from hormone‑producing cells. To see these tumors, a special type of scan called PET-CT is used. The scan works by injecting a tiny amount of a substance that gives off a signal that the scanner can detect. In this trial the new substance contains a radioactive form of copper, identified as V-Cu64, which is attached to a molecule named DOTATOC. The standard substance used in current practice contains a radioactive form of gallium, called 68Ga, also linked to the same molecule. The main goal is to find out whether the new copper‑based agent provides images that are as clear as those from the gallium‑based agent.

Participants will receive an injection of the copper‑based agent and then undergo a scan. After a short break, they will receive the standard gallium‑based agent and have a second scan. Doctors will compare the number of tumors seen and a measurement called SUV_MAX, which reflects how bright each tumor appears on the images. The study also includes monitoring for any side effects. The overall time each participant spends in the study is limited to a few visits over several weeks.

The research process

The trial runs in 3 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial imaging with 68ga‑labeled dotatoc

    After enrolment, you attend the first appointment at the imaging centre.

    A healthcare professional inserts a small needle into a vein (intravenous) and injects 200 mbq of 68ga‑labeled dotatoc. mbq stands for megabecquerel, a unit that measures radioactivity.

    Shortly after the injection, you lie on a table while a pet‑ct scanner creates detailed pictures of any neuroendocrine tumor tissue.

    The whole procedure usually takes a few hours, after which you can leave the centre.

  2. Step 2

    Second imaging with v‑cu64‑labeled dotatoc

    On a later date within the study period, you return for the second imaging session.

    Again, a needle is placed in a vein and 200 mbq of v‑cu64‑labeled dotatoc is injected. v‑cu64 is a radioactive form of copper used for imaging.

    The pet‑ct scanner is used in the same way to obtain images of the same areas examined previously.

    The duration of this visit is similar to the first, lasting a few hours.

  3. Step 3

    Safety monitoring and follow‑up

    After each imaging session, you are asked to report any new symptoms or discomfort to the study staff.

    The study records any adverse events, which are any unwanted medical occurrences, to evaluate safety of the radiopharmaceuticals.

    No additional medication is taken beyond the described injections.

Who can join the trial?

6 criteria

  • You must have a confirmed or suspected neuroendocrine tumor (NET) based on a tissue sample examined by a pathologist (called a histology/biopsy report).
  • You must have a confirmed or suspected NET shown by imaging tests such as an MRI (magnetic resonance imaging), a CT scan with contrast (x‑ray pictures with a dye to highlight structures), or special scans called PET‑CT (using either FDG or NaF tracers). These scans must have been done within the last 8 weeks.
  • You must have a confirmed or suspected NET based on blood or urine tests that show higher than normal levels of substances such as chromogranin A, pancreatic polypeptide, neuron‑specific enolase, vasoactive intestinal peptide, serotonin (measured as 5‑HIAA in urine), gastrin, somatostatin, catecholamines, metanephrine, calcitonin, fasting insulin, C‑peptide (or proinsulin), and glucagon.
  • If you have a family history that puts you at higher risk for NET, such as known genetic conditions called MEN1 or VHL, you may be eligible, whether you have symptoms or not.
  • Your recent blood work must be within safe limits: white blood cells higher than 2 × 10⁹ per liter, hemoglobin (the protein that carries oxygen) above 8.0 g/dL, platelets (cells that help clot blood) above 50 × 10⁹ per liter, and kidney function measured by serum creatinine below 170 µmol/L.
  • You must have a negative urine or blood pregnancy test, or be postmenopausal for at least 2 years, or have had a hysterectomy, and you must agree to use barrier or hormonal birth control during the study and for at least 3 months after it ends.

Who cannot join the trial?

5 criteria

  • Pregnancy or lactation: You cannot take part if you are currently pregnant or are nursing a baby.
  • Inability to give written consent: You must be able to sign a form agreeing to join the study; if you cannot do this, you are excluded.
  • Use of somatostatin analogue within the past 28 days: This means any medication that works like the natural hormone somatostatin (used to treat certain tumors) must not have been taken in the four weeks before the scan.
  • Serious health problems: Includes uncontrolled congestive heart failure (the heart cannot pump blood well), liver dysfunction (the liver is not working properly), renal dysfunction (the kidneys are not working properly), or uncontrolled high blood pressure (hypertension). If you have any of these conditions, you cannot participate.
  • History of hypersensitivity: If you have had an allergic reaction to drugs that are chemically similar to the study medication or to any of its inactive ingredients (called excipients), you are not eligible.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • V-Cu64

    is a radioactive copper‑based tracer that is attached to a molecule called DOTATOC. In this study it is the new test agent that is injected into the patient before a PET‑CT scan. The purpose is to see if it can show neuroendocrine tumors as clearly as the standard method.

  • V-Ga68

    is a radioactive gallium‑based tracer also linked to DOTATOC. It is used as the comparator, or “gold standard,” in the trial. Patients receive this agent before a PET‑CT scan to provide the reference images that the new test will be compared against.

  • Gallium‑68 DOTATOC

    is a well‑known radiopharmaceutical that binds to receptors on neuroendocrine tumor cells. It is injected before a PET‑CT scan to highlight the tumors, helping doctors locate and assess them. In the trial it serves as background information to show how the standard imaging works.

  • SomaKit TOC

    is a preparation kit that contains the peptide DOTATOC. The kit is used to make the radiopharmaceuticals (like the gallium‑68 or copper‑64 versions) by adding the radioactive metal. It provides the essential component that allows the tracer to target tumor cells during imaging.

What is already known about the treatment

  • Gallium-68 chloride

    This radiopharmaceutical is given by intravenous injection as a sterile solution and is used as a precursor to make imaging agents for PET scans. It is an established diagnostic substance that appears in medical literature for detecting tumors, especially neuroendocrine tumors. The compound emits positrons that allow PET‑CT scanners to create pictures of where the tracer gathers in the body. It belongs to the class of other diagnostic radiopharmaceuticals for tumor detection (ATC V09IX).

  • Copper-64 chloride

    This radioactive copper salt is administered intravenously as a solution and serves as the building block for the experimental PET imaging agent labeled DOTATOC. It is a newer tracer that is still being investigated in clinical studies for tumor imaging, with limited but growing published data. Copper‑64 emits positrons that enable high‑resolution PET images of neuroendocrine tumors when attached to a targeting molecule. It is classified as a diagnostic radiopharmaceutical for tumor detection (ATC V09IX).

  • Gallium-68 edotreotide

    The product is injected intravenously as a ready‑to‑use solution that already contains the radioactive gallium bound to the peptide edotreotide. Gallium‑68 edotreotide is a widely accepted PET imaging agent and is considered the gold‑standard for locating neuroendocrine tumors. It works by the gallium emitting positrons while the edotreotide part seeks out specific receptors on tumor cells, highlighting them on the scan. It falls under the category of diagnostic radiopharmaceuticals for tumor detection (ATC V09IX09).

  • SomaKit TOC (edotreotide kit)

    This kit is supplied as a sterile solution for injection and is used to prepare the gallium‑68 edotreotide tracer at the point of care by adding the radioactive gallium. The kit is a standard, commercially available product that has been used for many years in PET imaging of neuroendocrine tumors. After preparation, the edotreotide component binds to tumor‑cell receptors, while the attached gallium produces the PET signal. It is classified as a diagnostic radiopharmaceutical kit for tumor detection (ATC V09IX09).

Investigated diseases

Neuroendocrine tumor - A growth that starts in cells that release hormones into the blood. These tumors can appear in many parts of the body, most often in the pancreas or gastrointestinal tract. They may grow slowly and stay small for a long time, or they can become larger and form new lumps. Over time, the tumor cells can spread to nearby lymph nodes or distant organs. The size and number of tumors may increase as the condition progresses.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2025-524050-34-01Protocol codeCuDota25Estimated enrolment80 patients

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).